EFFICACY AND SAFETY OF NEMTABRUTINIB IN RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA: UPDATED ANALYSIS OF COHORT F OF THE PHASE 2 BELLWAVE-003 STUDY

EHA Library, Alessandra Tucci, 4160294

CLINICAL CHARACTERISTICS AND OUTCOMES OF INCIDENTAL VS SYMPTOMATIC FOLLICULAR LYMPHOMA

EHA Library, Suheil Albert Atallah-Yunes, 4160295

REAL-WORLD TREATMENT PATTERNS AND OUTCOMES IN HIGH-RISK, TREATMENT-NAIVE MANTLE CELL LYMPHOMA: A MULTINATIONAL ANALYSIS FROM THE UK, SWEDEN, AND FRANCE

EHA Library, Alex Smith, 4160296

FREE LIGHT CHAIN (FLC) RATIO IS AN INDEPENDENT PROGNOSTIC RISK FACTOR FOR PROGRESSION TO SYMPTOMATIC WALDENSTROM'S MACROGLOBULINEMIA

EHA Library, Gianmarco Favrin, 4160297

EZH2 MUTATION STATUS IS NOT PREDICTIVE IN R-CHOP AND R-B TREATED FOLLICULAR LYMPHOMA PATIENTS - A MULTICENTRIC COHORT STUDY AND META-ANALYSIS

EHA Library, Richárd Hanza, 4160298

REAL WORLD EXPERIENCE FINDS NO DIFFERENCE IN TIME TO 2ND LINE TREATMENT BETWEEN OBINUTUZUMAB AND RITUXIMAB-CONTAINING REGIMENS AMONG PATIENTS WITH FOLLICULAR LYMPHOMA

EHA Library, Dor Shpitzer, 4160299

RISK OF LYMPHOMA AND OTHER HAEMATOLOGIC MALIGNANCIES IN INCIDENTALLY DETECTED SPLENOMEGALY: PROSPECTIVE STUDY OF 47,066 CT/MR SCANNED GENERAL POPULATION INDIVIDUALS FROM DENMARK AND THE UNITED KINGDOM

EHA Library, Anne Rudbeck Juhl, 4160300

IMPACT OF TP53 MUTATION STATUS ON OUTCOMES AFTER FIRST-LINE TREATMENT IN LYMPHOPLASMACYTIC LYMPHOMA.

EHA Library, Sherif Seif, 4160301

COMPARATIVE EFFECTIVENESS OF ODRONEXTAMAB VERSUS REAL-WORLD SYSTEMIC THERAPIES USED IN AN EXTERNAL CONTROL ARM IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Emmanuel Bachy, 4160302

CLINICAL CHARACTERISTICS AND MOLECULAR HETEROGENEITY IN FOLLICULAR LYMPHOMA WITH EXTRANODAL INVOLVEMENT

EHA Library, WeiLi Zhao, 4160303

ORELABRUTINIB COMBINED WITH BENDAMUSTINE-RITUXIMAB OR OBINUTUZUMAB FOLLOWED BY ORELABRUTINIB MAINTENANCE IN UNTREATED MARGINAL ZONE LYMPHOMA (OPTIMIZE): A MULTICENTER, SINGLE-ARM, PHASE II STUDY

EHA Library, Wenjuan Yu, 4160304

REAL-WORLD BURDEN OF DISEASE, TREATMENT PATTERNS AND OUTCOMES IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)

EHA Library, Alvaro J. Alencar, 4160305

MATCHING-ADJUSTED INDIRECT COMPARISON OF LISOCABTAGENE MARALEUCEL VERSUS AXICABTAGENE CILOLEUCEL AND TISAGENLECLEUCEL FOR TREATMENT OF THIRD-LINE OR LATER R/R FL: UPDATE WITH 24 MONTHS OF FOLLOW-UP

EHA Library, Alexander P. Boardman, 4160306

INCIDENCE AND SURVIVAL OUTCOMES OF PRIMARY PAROTID FOLLICULAR LYMPHOMA (PPFL): A SEER-BASED RETROSPECTIVE ANALYSIS

EHA Library, Jeyapradeeban Arunachalam, 4160307

FEATURES AND OUTCOMES OF ASYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA IN RELATION TO BONE MARROW INFILTRATION: AN ITALIAN UNIVERSITY HOSPITAL ANALYSIS

EHA Library, Nicolò Danesin, 4160308

LONG-TERM RESULTS OF THE „MCL-2016” PROTOCOL IN PATIENTS WITH MANTLE CELL LYMPHOMA IN DIFFERENT PROGNOSTIC GROUPS

EHA Library, Daria Koroleva, 4160309

RARE LYMPHOID MALIGNANCIES; EPIDEMIOLOGICAL CHARACTERISTICS AT THE POPULATION LEVEL

EHA Library, Marc Maynadié, 4160310

A PROSPECTIVE, MULTICENTER, SINGLE-ARM STUDY ON THE COMBINATION OF ORELABRUTINIB AND RITUXIMAB IN THE SECOND-LINE TREATMENT OF RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA

EHA Library, Lixia Sheng, 4160311

IMPACT OF BASELINE SUVMAX IN UNTREATED HIGH-TUMOR-BURDEN FOLLICULAR LYMPHOMA

EHA Library, Ikram Bouguern, 4160312

REAL-WORLD EVIDENCE ON MOGAMULIZUMAB FOR SÉZARY SYNDROME AND MYCOSIS FUNGOIDES IN PATIENTS AGED 75 AND OLDER.

EHA Library, Erika Morsia, 4160313

GOLIDOCITINIB MONOTHERAPY IN THE TREATMENT OF REFRACTORY/RELAPSED INDOLENT T/NK-CELL LYMPHOMA: PRELIMINARY RESULTS FROM T-LGLL COHORT

EHA Library, Ying Yu, 4160314

PROGRESSION-FREE SURVIVAL IMPROVEMENT OF LOCALIZED OCULAR ADNEXAL MALT LYMPHOMA PATIENTS WITH RESIDUAL LESIONS: COMPARATIVE OUTCOME OF POSTOPERATIVE TREATMENT VERSUS WATCHFUL WAITING

EHA Library, Jun Shi, 4160315

A PHASE 2 STUDY OF TAZEMETOSTAT (TAZ) IN CHINESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) HARBORING ENHANCER-OF-ZESTE-HOMOLOG-2 MUTATIONS (EZH2MUT)

EHA Library, Junning Cao, 4160316

THE PROGNOSTIC ROLE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) IN WALDENSTRÖM MACROGLOBULINEMIA: AN INDEPENDENT PROGNOSTIC MARKER

EHA Library, David Kaldas, 4160317

EFFICACY AND SAFETY OF ACADEMIC ANTI-CD19 CAR-T CELL THERAPY FOR RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA

EHA Library, Katsiaryna Zharkova, 4160318

THE REAL-WORLD EFFICACY AND SAFETY OF OBINUTUZUMAB-BASED INDUCTION THERAPY FOR UNTREATED FOLLICULAR LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE ANALYSIS

EHA Library, Fangfang LYU, 4160319

REAL-WORLD ZANUBRUTINIB TREATMENT PATTERNS IN MANTLE CELL LYMPHOMA AMONG US COMMUNITY ONCOLOGY PATIENTS WITH PRIOR BRUTON TYROSINE KINASE INHIBITOR THERAPY

EHA Library, Rushir Choksi, 4160320

MINIMAL RESIDUAL DISEASE-GUIDED THERAPY WITH ORELABRUTINIB AND RITUXIMAB IN TREATMENT-NAÏVE MARGINAL ZONE LYMPHOMA

EHA Library, Wenzhe Yan, 4160321

POSITRON EMISSION TOMOGRAPHY-ADAPTED THERAPY IN LOW-RISK DIFFUSE LARGE B-CELL LYMPHOMA: 4-YEAR RESULTS OF A RANDOMIZED, PHASE III, NON-INFERIORITY TRIAL

EHA Library, Qing Shi, 4160322

PET GUIDED OMISSION OF RADIOTHERAPY IN ELDERLY DLBCL PATIENTS WITH LESS FAVOURABLE PROGNOSIS IS SAFE: RESULTS OF 863 PATIENTS TREATED IN THE OPTIMAL>60 TRIAL OF THE DSHNHL/GLA

EHA Library, Viola Pöschel, 4160323

RELMACABTAGENE AUTOLEUCEL (RELMA-CEL) AS SECOND-LINE THERAPY FOR R/R AGGRESSIVE B-NHL IN PATIENTS INELIGIBLE FOR HDCT/ASCT: PRIMARY ANALYSIS FROM A PHASE 2 STUDY

EHA Library, Qingqing Cai, 4160324

PROMISING EFFICACY OF AT101, A NOVEL ANTI-CD19 CAR-T THERAPY, IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA: INTERIM ANALYSIS OF A MULTICENTER PHASE 2 TRIAL

EHA Library, Dok Hyun Yoon, 4160325

SUSTAINED REMISSION IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA WITH EPCORITAMAB MONOTHERAPY: EPCORE NHL-1 3-Y RESULTS AND NOVEL SUBGROUP ANALYSES IN PATIENTS WITH COMPLETE RESPONSE AT 2 Y

EHA Library, Chan Y. Cheah, 4160326

POLATUZUMAB VEDOTIN, RITUXIMAB, AND LENALIDOMIDE (POLA-R2) AS FIRST-LINE THERAPY FOR UNFIT AND FRAIL ELDERLY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: PRELIMINARY RESULTS FROM A PROSPECTIVE, PHASE II, MULTI-CENTER STUDY

EHA Library, Wei Wang, 4160327

NOVEL ZCR (ZANUBRUTINIB, CHIDAMIDE, RITUXIMAB) ± CHOP REGIMEN DEMONSTRATES PROMISING EFFICACY IN FRONTLINE TREATMENT OF DOUBLE-EXPRESSOR DIFFUSE LARGE B-CELL LYMPHOMA(DE-DLBCL)

EHA Library, Zhi-Ming Li, 4160328

ZANUBRUTINIB IN COMBINATION WITH R-CHOP FOR PREVIOUSLY UNTREATED MCD TYPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

EHA Library, Wenjuan Yu, 4160329

THREE-HOUR INFUSION OF METHOTREXATE AT 3 G/M2 SIGNIFICANTLY REDUCES CNS RECURRENCES AND IMPROVES SURVIVAL IN LARGE B-CELL LYMPHOMAS WITH INCREASED CNS RISK: ANALYSIS OF A SINGLE-CENTER COHORT OF 501 PATIENTS

EHA Library, Andrés Ferreri, 4160330

ANTI-CD19 CAR-T CELL THERAPY IN RELAPSED/REFRACTORY T-CELL/HISTIOCYTE-RICH LARGE B-CELL LYMPHOMA (THRLBCL): INSIGHTS FROM THE FRENCH DESCAR-T REGISTRY, A LYSA STUDY.

EHA Library, Axel Andre, 4160331

IBRUTINIB DOSE MODIFICATION IN MANTLE CELL LYMPHOMA: AN ITALIAN REAL-LIFE MULTICENTER EXPERIENCE. RESULTS FROM THE REDOT_MCL STUDY.

EHA Library, Luca Pagliaro, 4160332

ZANUBRUTINIB AND RITUXIMAB REGIMEN COMBINED WITH INTRAVITREAL METHOTREXATE FOR PRIMARY VITREORETINAL LYMPHOMA: A PHASE II STUDY

EHA Library, Zhe Zhuang, 4160333

THE IMPACT OF SOCIOECONOMIC STATUS ON SURVIVAL OF PATIENTS WITH LARGE B-CELL LYMPHOMA IN FINLAND, A POPULATION-BASED ANALYSIS

EHA Library, Joonas Kuitunen, 4160334

MOLECULAR FEATURES ENCODED IN THE DYNAMIC CTDNA MONITORING REVEAL ADDITIONALLY PROGNOSTIC VALUE, DIFFERENT CLINICAL COURSES AND CLONE EVOLUTION FOR DIFFERENT GENETIC SUBTYPES OF DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Jinhua Liang, 4160335

FOLLICULAR LYMPHOMA: A REPORT FROM THE DANISH LYMPHOMA REGISTRY ON THE TREATMENT APPROACHES AND OUTCOMES IN NEWLY DIAGNOSED PATIENTS

EHA Library, Jelena Jelicic, 4160336

THE PROGNOSTIC VALUE OF CIRCULATING CELL-FREE METHYLATED EBV-DNA IN EXTRANODAL NK/T CELL LYMPHOMA

EHA Library, Jinhua Liang, 4160337

MOLECULAR SUBTYPE-GUIDED TARGETED THERAPY COMBINED WITH R-MINE (R-MINE+X) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-ARM, OPEN-LABEL, MULTICENTER PHASE II STUDY

EHA Library, Jinhua Liang, 4160338

SUPERIOR OUTCOMES OF AUTOLOGOUS TRANSPLANTATION VERSUS CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN RELAPSED CNS LYMPHOMA TREATED IN COMPLETE REMISSION

EHA Library, Yuelu Guo, 4160339

BMS-986458, A FIRST-IN-CLASS, BIFUNCTIONAL CEREBLON-DEPENDENT LIGAND-DIRECTED DEGRADER (LDD) OF B-CELL LYMPHOMA 6 (BCL6) IN PATIENTS WITH RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA: INITIAL PH 1 RESULTS

EHA Library, Franck Morschhauser, 4160340

ZANUBRUTINIB IN COMBINATION WITH R-MTX FOR NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Xibin Xiao, 4160341

CAR T-CELL THERAPY IS EFFICIENT IN VITREORETINAL LYMPHOMAS. A LOC NETWORK STUDY.

EHA Library, cecile pivert, 4160342

INCIDENCE AND SURVIVAL OF PRIMARY CNS LYMPHOMA: AN ENGLAND-WIDE COHORT STUDY FROM THE UNCOVER STUDY GROUP

EHA Library, Sarrah Tayabali, 4160343

SAFETY AND EFFICACY OF DUAL-TARGET CD19/CD20 CAR-T THERAPY IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

EHA Library, Liu Rui, 4160344

OVERALL SURVIVAL IMPROVEMENT OF THE R/R DLBCL PATIENT POPULATION TREATED IN THE YEAR 2021 AND BEYOND

EHA Library, Marek Trneny, 4160345

PROGNOSTIC SIGNIFICANCE OF SEQUENTIAL CIRCULATING-TUMOR DNA ASSESSMENTS IN PATIENTS WITH ADVANCED STAGE DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH R-CHOP IMMUNOCHEMOTHERAPY

EHA Library, Ga-Young Song, 4160346

LONG-TERM EFFICACY OF COMPLETE REMISSION PATIENTS WITH R/R DIFFUSE LARGE B-CELL LYMPHOMA AFTER CAR-T THERAPY: BTK INHIBITOR MAINTENANCE TREATMENT MAY PROLONG REMISSION DURATION

EHA Library, Liu Rui, 4160347

IMPACT OF PRE-INFUSION CD19 EXPRESSION ON CAR T-CELL EXPANSION AND CLINICAL OUTCOMES IN R/R -B-CELL LYMPHOMA.

EHA Library, Ilenia De Bernardis, 4160348

EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN, ZANUBRUTINIB AND RITUXIMAB (POLA-ZR) IN UNTREATED ELDERLY AND FRAIL DLBCL PATIENTS: A PROSPECTIVE PHASE 2 CLINICAL TRIAL

EHA Library, Yuhong Ren, 4160349

BISPECIFIC ANTIBODIES AS HOLDING OR BRIDGING THERAPY BEFORE CAR-T IN LARGE B-CELL LYMPHOMA

EHA Library, Hanna Katharina Zieger, 4160350

THE RESULT OF A SINGLE-ARM, PHASE IB, MULTI-CENTER STUDY OF RITUXIMAB, ACALABRUTINIB, AND DURVALUMAB (RAD) IN THE RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)

EHA Library, Kwang-Yu Chang, 4160351

CLINICAL OUTCOMES OF NEWLY DIAGNOSED PCNSL TREATED WITH RITUXIMAB-METHOTREXATE-CYTARABINE WITH OR WITHOUT IBRUTINIB: A RETROSPECTIVE STUDY

EHA Library, Wenhua Wang, 4160352

BOOM-BOOM RADIATION PRIOR TO LISOCABTAGENE MARALEUCEL IS FEASIBLE AND CONTRIBUTES TO HIGH COMPLETE RESPONSE RATES FOR AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA

EHA Library, Christopher D'Angelo, 4160353

COMBINING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH CD19/CD22 DUAL-TARGET CAR-T THERAPY: A PROMISING STRATEGY FOR REFRACTORY AND RELAPSED HIGH-RISK B-CELL LYMPHOMA

EHA Library, Xian Zhang, 4160354

REAL-WORLD OUTCOMES OF MITOXANTRONE HYDROCHLORIDE LIPOSOME REGIMEN FOR PERIPHERAL T-CELL LYMPHOMA: A SHORT-TERM EFFICACY AND SAFETY ANALYSIS OF TREATMENT-NAÏVE POPULATION (MOMENT)

EHA Library, Ma Jun, 4160355

POMALIDOMIDE, RITUXIMAB, ORELABRUTINIB, AND MINICHOP-LIKE (PRO-MINICHOP) IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: UPDATED RESULTS FROM A PHASE II STUDY

EHA Library, Na-Na Ping, 4160356

EPIDEMIOLOGICAL AND SURVIVAL TRENDS OF ALK-POSITIVE LARGE B-CELL LYMPHOMA: A SEER (SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS) STUDY

EHA Library, Jeyapradeeban Arunachalam, 4160357

CONTROLLING NUTRITIONAL STATUS (CONUT) SCORE AS A PROGNOSTIC FACTOR FOR SURVIVAL IN CAR-T THERAPY FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA

EHA Library, Yuelu Guo, 4160358

A PHASE II STUDY OF DUAL EPIGENETIC MODULATION WITH OBINUTUZUMAB/LIPOSOMAL MITOXANTRONE IN CHEMORESISTANT DLBCL PATIENTS POST-SALVAGE THERAPY

EHA Library, Chang-Ju Qu, 4160359

REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL): A SYSTEMATIC LITERATURE REVIEW (SLR) AND META-ANALYSIS

EHA Library, Olalekan Oluwole, 4160360

INTRAVENOUS MIDDLE-DOSE METHOTREXATE INCORPORATED INTO R-CHOP PREVENTED CENTRAL NERVOUS SYSTEM RELAPSE IN HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Min Lang, 4160361

REAL-WORLD OUTCOMES OF POLA-RB (POLATUZUMAB VEDOTIN, RITUXIMAB, BENDAMUSTINE) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: INSIGHTS FROM THE POLISH LYMPHOMA RESEARCH GROUP

EHA Library, Magdalena Olszewska-Szopa, 4160362

CYTOKINE RELEASE SYNDROME (CRS) AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN LYMPHOMA PATIENTS RECEIVING AXICABTAGENE CILOLEUCEL: ANALYSIS BY YEAR OF TREATMENT AND INDICATIONS

EHA Library, Anna Dodero, 4160363

TREATMENT OUTCOMES AND PROGNOSTIC FACTORS IN PRIMARY MEDIASTINAL B-CELL LYMPHOMA: MULTICENTER REAL-WORLD DATA OF 166 PATIENTS

EHA Library, Selin Küçükyurt, 4160364

PHASE 2 NIVO-ALCL STUDY OF NIVOLUMAB FOR RELAPSE/REFRACTORY ALK+ ANAPLASTIC LARGE CELL LYMPHOMA, FOR PATIENTS WITH PROGRESSIVE DISEASE OR AS CONSOLIDATIVE IMMUNOTHERAPY AFTER COMPLETE REMISSION.

EHA Library, Charlotte Rigaud, 4160365

VALIDATION OF ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) SCORE IN KOREAN AITL PATIENTS

EHA Library, bohyun moon, 4160366

ROBUST SINGLE AGENT ACTIVITY OF BI-1808, A TUMOR NECROSIS FACTOR RECEPTOR 2 (TNFR2) BLOCKER/DEPLETER, IN CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS

EHA Library, Stefan Barta, 4160367

PHASE 2 STUDY OF DZD8586, A NON-COVALENT BBB PENETRANT LYN/BTK DUAL INHIBITOR, AS MONOTHERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: TAI-SHAN9 TRIAL

EHA Library, lugui qiu, 4160368

COMBINATION OF MITOXANTRONE HYDROCHLORIDE LIPOSOME WITH GEMCITABINE, CISPLATIN AND DEXAMETHASONE (MGDP) IN PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T CELL LYMPHOMA: A PROSPECTIVE, SINGLE-ARM, MULTICENTER, PHASE I/II STUDY

EHA Library, Chong Wei, 4160369

CLINICOPATHOLOGIC FEATURES AND SURVIVAL OUTCOMES OF POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE BY LIVER TRANSPLANT DONOR GRAFT TYPE

EHA Library, Seong-Eun Kim, 4160370

PROPENSITY SCORE-MATCHED ANALYSIS SUPPORTS THE SURVIVAL BENEFITS OF CAR-T THERAPY WITH TANDEM STEM CELL SUPPORT IN NHL: INSIGHTS FROM A REAL-WORLD STUDY IN CHINA

EHA Library, Haiwen Huang, 4160371

PRIMARY EFFICACY AND SAFETY OF FIRST-LINE R-MTO REGIMEN (RITUXIMAB, METHOTREXATE, THIOTEPA, AND ORELABRUTINIB) FOLLOWED BY AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PCNSL

EHA Library, Zengjun Li, 4160372

A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF CLINICAL CHARACTERISTICS AND TREATMENT OUTCOMES IN 104 NEWLY DIAGNOSED ENKTL PATIENTS

EHA Library, Haiwen Huang, 4160373

A NOVEL PROGNOSTIC MODEL FOR PREDICTING DISEASE PROGRESSION AND SURVIVAL IN PRIMARY LARGE B-CELL LYMPHOMA OF IMMUNE-PRIVILEGED SITES

EHA Library, Ganggang Wang, 4160374

REAL-WORLD ANALYSIS OF GLOFITAMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Zhiyong Zeng, 4160375

PERSONALIZED GENETICALLY ADAPTED THERAPY FOR NEWLY DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-CENTER PROSPECTIVE STUDY

EHA Library, Marat Mingalimov, 4160376

SAFETY AND EFFECTIVENESS OF BRENTUXIMAB VEDOTIN IN CHINESE CD30-POSITIVE LYMPHOMA ADULTS: AN INTERIM ANALYSIS FROM BRAVE STUDY

EHA Library, WeiLi Zhao, 4160377

LORLATINIB THERAPY IN RELAPSED/REFRACTORY ALK + LYMPHOMAS PREVIOUSLY TREATED WITH TYROSINE KINASE INHIBITORS

EHA Library, Carlo Gambacorti-Passerini, 4160378

KMT2A MUTATIONS CONFER ADVERSE PROGNOSIS IN PERIPHERAL T-CELL LYMPHOMA: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Youngwoo Jeon, 4160379

LOW SOCIOECONOMIC STATUS IS ASSOCIATED WITH AN INFERIOR PROGNOSIS IN DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS DESPITE THE AGE

EHA Library, Milla Elvi Linnea Kuusisto-Jauhiainen, 4160380

SINGLE-CELL ANALYSIS OF CIRCULATING IMMUNE HETEROGENEITY IN DLBCL HIGHLIGHTS DISTINCT IMMUNE CELL SIGNATURES IN IMMUNOTHERAPY

EHA Library, Sicong Zhang, 4160381

FREQUENCY AND PROGNOSIS OF T-CELL DISORDERS IN ADULT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS

EHA Library, Kamolchanok Tanchotikul, 4160382

SAFETY AND EFFICACY OF CAR-T THERAPY IN AUTOLOGOUS STEM CELL TRANSPLANTATION-FAILURE B-CELL NON-HODGKIN LYMPHOMA PATIENTS: A RETROSPECTIVE ANALYSIS

EHA Library, Liu Rui, 4160383

CASPASE-3 AND CASPASE-7 AS PREDICTOR FACTORS OF RESPONSE AND RESISTANCE IN CEREBROSPINAL FLUID (CSF) IN PATIENTS WITH LYMPHOID MALIGNANCIES

EHA Library, Maher Salamoon, 4160384

A NOVEL PROGNOSTIC MODEL INCORPORATING SERUM ß2-MICROGLOBULIN IN PRIMARY CNS LYMPHOMA

EHA Library, Yeokyeong Shin, 4160385

EFFICACY OF POLA-R-CHP IN PREVIOUSLY UNTREATED CD5-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Junqing Xu, 4160386

CRP-ALBUMIN-LYMPHOCYTE (CALLY) INDEX: A PROMISSING PROGNOSTIC TOOL IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Zorica Cvetković, 4160387

HYPER-FRACTIONATED RADIOTHERAPY BRIDGING CAR-T FOR AGGRESSIVE B-CELL CNS LYMPHOMA

EHA Library, Jing Ruan, 4160388

COMPARISON OF WHOLE BRAIN RADIOTHERAPY (RT) VERSUS AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): A REAL WORLD PROPENSITY SCORE (PS) MATCHING ANALYSIS

EHA Library, Jiao Jie Cherie Tan, 4160389

POLA-R-CHP PERFORMED WELL IN POLARIX TRIAL-INELIGIBLE AND LOW RISK (IPI 0-1) PATIENTS WITH PREVIOUSLY UNTREATED DLBCL: A PROSPECTIVE OBSERVATIONAL STUDY

EHA Library, Yuhong Ren, 4160390

THE ABSOLUTE MONOCYTE AND LYMPHOCYTE PROGNOSTIC MODEL IDENTIFIES HIGH-RISK PATIENTS AND PREDICTS OUTCOMES IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Wenhui Guo, 4160391

REAL WORLD DATA ON USE OF RITUXIMAB IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTED PATIENTS.

EHA Library, Lay Khandwala, 4160392

SINGLE-CELL ATLAS OF PRIMARY CNS LYMPHOMA REVEALS AN IMMUNE-RICH TUMOUR MICROENVIRONMENT MODULATED BY ENDOTHELIAL CELLS AND CANCER-ASSOCIATED FIBROBLASTS

EHA Library, Keir Pickard, 4160393